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Sphingolipids were discovered more than a century ago in the brain. Cerebrosides and sphingomyelins were named so because they were first
isolated from neural tissue. Although glycosphingolipids and especially those containing sialic acid in their oligosaccharide moiety are particularly
abundant in the brain, sphingolipids are ubiquitous cellular membrane components. They form cell- and species-specific profiles at the cell
surfaces that characteristically change in development, differentiation, and oncogenic transformation, indicating the significance of these lipid
molecules for cell–cell and cell–matrix interactions as well as for cell adhesion, modulation of membrane receptors and signal transduction. This
review summarizes sphingolipid metabolism with emphasis on aspects particularly relevant in neural cell types, including neurons,
oligodendrocytes and neuroblastoma cells. In addition, the reader is briefly introduced into the methodology of lipid evaluation techniques and
also into the putative physiological functions of glycosphingolipids and their metabolites in neural tissue.
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Neural tissue has evolved to become highly specialized for
the conduction of electrical impulses that transmit information
or instructions from one region of the body to another. About
98% of neural tissue is concentrated in brain and spinal cord,
the central nervous system. Interestingly the gastro-intestinal
tract, often called “the second brain”, or the enteric nervous
system, contains the highest number of neurons apart of the
brain. Neural tissue contains two basic types of cells—
neurons and neuroglia (or glia) and their dynamic interaction
represents the fundamental functional unit of the nervous
system (Fig. 1). A common morphological characteristic of all
neuronal cells is a largely extended cell surface area due to
specialized membrane extensions—dendrites and axons (Fig.
1). Accordingly, vital neural functions including information
flux and transduction occur along these cellular membranes.
1.1. Glycosphingolipid profiles of neural cell types
J. L. W. Thudichum (1884) discovered sphingolipids (SLs)
while studying the chemical composition of the brain. He
named the backbone of all SLs “sphingosine” after the sphinx in
Greek mythology due to its enigmatic properties. Sphingolipids
are often classified as ceramides, sphingomyelins and glyco-
sphingolipids (GSLs). They do not contain glycerol but their
long chain sphingoid backbone retains the two hydroxyl-groups
with the middle position occupied by an amine-group. Initially
several SL classes including cerebrosides and sphingomyelins
were designated after the tissue from which they were isolated,
leaving the impression that they occur only in neural tissue.
Although SLs are found in all eukaryotic tissues gangliosides, aFig. 1. Schematic representation of different cell types of the central nervous system (
stellate cells with numerous processes communicating with several other cell typ
oligodendrocytes via their soma and processes. Further contacting cell types are other
barrier. Oligodendrocytes are the myelinating cells by sending glial processes forming
cells are regulated by gap junctions, forming a glial network. Neurons receive signal
fibers via their axons and synapses (arrow). Microglia are small non-neuronal inters
waste products of the nerve tissue. Microglia are also involved in formation of the bclass of sialic acid-containing GSLs are particularly abundant in
the central nervous system. As depicted in Fig. 2 different
neural cell types express characteristic GSL profiles. Complex
gangliosides, known to carry most of the sialic acid present in
brain [1], are characteristic components of neuronal cells and
are localized in the external leaflet of their plasma membranes.
Neuronal ganglioside profiles vary in different regions of the
brain and characteristically change during ontogenesis [2–8].
Otherwise, oligodendrocytes specifically express galactosylcer-
amide (GalCer) and sulfatide (see below), while the GSL pattern
of astrocytes exhibits high similarity with that of fibroblasts
(Fig. 2). Ganglioside profiles may also change as a result of
insult upon cell, like cell transformation. Thus the amount of
complex gangliosides is drastically reduced in neuroblastoma
cells when compared to highly differentiated, post-mitotic
neurons (Fig. 2). Based on these findings, the question
addressing the involvement of gangliosides in tumour progres-
sion was intensively studied (for review see [9]). Since this
aspect is beyond the scope of the present review, we just want to
point to an interesting hypothesis regarding a possible
mechanism, which correlates GSL metabolism with cell cycle
progression and thus with cell fate decisions, pro- or anti-cancer.
This might be of significance also in neural tissue [10].
1.2. Glycosphingolipids in disease and neural development
Experimental evidence shows that neural GSLs are able to
modulate protein structure via selective interaction. This
appears of particular importance for (i) amyloid β-peptides
(Aβ), found in extracellular deposits in brains of Alzheimer's
diseased patients, and (ii) for prion proteins [11–21]. Beyond
this structural modulation, GSLs also appear to be implicated inCNS). Astrocytes and oligodendrocytes are glial cells of the CNS. Astrocytes are
es like neurons by interacting with their soma, dendrites and axons or with
astrocytes and endothelial cells around blood capillaries forming the blood–brain
compact myelin spiraling around axons. A number of interactions between glial
s via their dendrites and send information to other neurons or innervated muscle
titial cells of various forms that are migratory and act as phagocytes to remove
lood–brain barrier.
Fig. 2. Metabolic labelling of glycosphingolipids of different cell types. Cells
were incubated for 48 h in the presence of [14C]galactose (2 μCi/ml) and
then harvested. GSLs were extracted, desalted, separated by thin layer
chromatography and visualized by fluorography as described previously [74].
Lane 1, primary cultured oligodendrocytes; lane 2, primary cultured
astrocytes; lane 3, neuroblastoma cells (B104); lane 4, fibroblasts; lane 5,
primary cultured cerebellar neurons. The mobility of standard lipids is
indicated. Note that all primary cultured neural cells were isolated from rat
brain, whereas fibroblasts were cultured from rat abdomen derived skin
[191]. Neuroblastoma B104 cells originate from rat central nervous system
tumours [192]. The terminology used for gangliosides is that of
Svennerholm [193]. Gbose3Cer, Galα1→4Galβ1→4Glcβ1→1Cer; Gbo-
se4Cer, GalNAcβ1→3 Galα1→4Galβ1→4Glcβ1→1Cer.
1980 G. van Echten-Deckert, T. Herget / Biochimica et Biophysica Acta 1758 (2006) 1978–1994the regulation of proteolytic processing and subcellular
transport of β-amyloid precursor protein (APP) as was recently
reported for different cell types including human neuroblastoma
SH-SY5Y cells [22]. The inhibition of GSL biosynthesis was
reported to reduce the secretion of APP and Aβ, whereas
addition of exogenous gangliosides reversed these effects [22].
Thus, GSL synthesis blockers may potentially open new
avenues for Alzheimer's disease therapy.
Interestingly, not only the membrane lipid composition
appears to modulate enzyme activities involved in APP
processing, but conversely APP derived peptides, the products
of these enzymatic reactions, were shown to regulate on their
part cellular lipid homeostasis [23]. This reciprocal regulation
appears to be essential in the pathology of Alzheimer's disease
[23]. Thus the levels of the phosphosphingolipid sphingomye-
lin, (see below) and of cholesterol control APP cleavage to Aβ
by regulating γ-secretase activity, whereas in turn, differently
formed cleavage products modulate enzymes involved in the
metabolism of sphingomyelin and cholesterol, thus controlling
the levels of these lipids.
Metabolism and function of complex GSLs were studied for
many years in primary cultured neurons, glia cells as well as in
cell lines derived thereof. A significant step towards under-
standing the function of complex sialylated GSLs was, however,the development of mice models deficient in distinct biosyn-
thetic steps. The first data from such knockout mice appeared to
be inconsistent with the long lasting assumption that ganglio-
sides are essential for brain development, a hypothesis based on
the finding that ganglioside profiles specifically change during
development (see above). Thus in mice lacking complex
gangliosides brain development was largely normal [24–27].
Even the double mutant mice that were able to produce only
GM3 as major brain ganglioside exhibited “only” fatal sound-
induced seizures [28]. However, mice unable to produce any
ganglioside have a very short lifespan with severe neurodegen-
eration, indicating that gangliosides are essential components
that help to stabilize the brain [29,30]. A crucial step towards
demonstrating a key function of gangliosides in the brain is the
recent discovery that a mutation of GM3 synthase and thus a
defective ganglioside synthesis causes epilepsy in humans [31].
This is the first report of a human disease based on a defect in
ganglioside biosynthesis, whereas numerous genetic diseases
are known that are linked to the degradation pathway of
gangliosides [32].
Over the past decade, besides gangliosides, the roles of their
metabolic precursors and breakdown products in neural
development and signalling have become clearer. Thus,
relatively simple SLs like glucosylceramide (GlcCer) and
ceramide, the hydrophobic membrane anchor of all SLs, were
found to be essential for neuronal development. Using primary
cultured hippocampal neurons, the group of A. H. Futerman
found that GlcCer and not gangliosides plays a key role in the
regulation of axonal growth (reviewed in [33] and references
therein). There is a huge and growing number of reports
covering the role of sphingolipid metabolites especially of
ceramide and sphingosine-1-phosphate (S1P) in neural signal-
ling and function. This important aspect has been extensively
reviewed recently by Colombaioni and Garcia-Gil [34]. It thus
becomes obvious that the metabolic SL machinery in neural
tissue is not only essential for a proper supply of membrane
components, but contributes to the complex regulation of
fundamental cellular events.
1.3. Challenges of metabolomics
The metabolome has been defined as the qualitative and
quantitative collection of all low molecular weight molecules
(metabolites) that participate in metabolic reactions and that are
required for the maintenance, growth, and normal (or abnormal)
function of a cell. A cellular metabolome is a complex,
involving several compound classes of small molecules
(peptides, amino acids, carbohydrates and lipids) that vary in
size, structure, polarity, functional groups, and in cellular and
subcellular concentrations.
While mRNA gene expression- and proteomics data collected
during the last decade do not disclose the entire story of what
might be happening in a cell, metabolic profiling can give an
instantaneous “snapshot” of the physiology of a cell or tissue. The
challenge of systems biology nowadays is to combine proteomics,
transcriptomics, and metabolomics (including lipidomics) infor-
mation to give a more comprehensive picture of living organisms.
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deeper understanding of cellular functioning, which is of great
interest for both academic and drug discovery research.
Metabolomics present unique challenges for sample collec-
tion and extraction for determining analyte identity, concentra-
tion, structure, activity, and flux in cells.
1.4. Lipid evaluation techniques
Technologies currently in use for lipid analyses include
chromatography, like thin layer chromatography (TLC) [35,36]
(example given in Fig. 2), nuclear magnetic resonance (NMR)
and mass spectrometry (MS). MS is used to identify and to
quantify metabolites after separation by gas chromatography
(GC), high performance liquid chromatography (HPLC) [37,38]
or capillary electrophoresis (CE). GC, especially when inter-
faced with mass spectrometry (GC-MS), is a widely used and
powerful method. It offers high chromatographic resolution, but
requires chemical derivatization for many biomolecules and
only volatile chemicals can be analyzed without derivatization.
Therefore, some large and polar metabolites cannot be analyzed
by GC. Compared to GC, HPLC has lower chromatographic
resolution, but it does have the advantage that a much wider
range of lipids can be measured. NMR is the only detection
technique, which does not rely on separation of the analytes, and
the sample can thus be recovered for further analyses. NMR is
close to being a universal detector, since all kinds of small
molecule metabolites can be measured simultaneously. But it
possesses the major disadvantage that it is relatively insensitive
compared to MS-based techniques. MS is both sensitive and can
be very specific. In addition, mass spectral fingerprint libraries
exist and may be developed further to allow identification of a
lipid according to its fragmentation pattern. Also matrix-assisted
laser desorption and ionization time-of-flight (MALDI-TOF),
well known for protein identification, was successfully applied
to lipid analyses. Each technology currently in use has
significant limitations in quantification, scope and/or throughput
and none of them can effectively measure, identify and quantify
with sufficient sensitivity and precision the diverse range of
lipids and phospholipids and their dynamic fluctuation in cells.
The unique and diverse physical properties of lipids make them
difficult to measure on one platform hence integrated set of
technologies, including powerful software tools to solve
bioinformatics problems, have to be accomplished. It is beyond
the scope of this review to address lipid technologies in more
detail. Therefore, we would like to refer to excellent reviews of
colleagues and the references therein [39–41].
2. Metabolism of ceramide
Ceramide, the hydrophobic membrane anchor of all sphingo-
lipids, is probably the lipid that attracted most attention during the
last decade—e.g. a new conference, the “CCC” (Charleston
Ceramide Conference), is dedicated to this lipid and the cosmetic
industry promotes its skin and hair protective properties (see
chapter “Ceramides in stratum corneum” by J. Bowstra, this
volume).Ceramide has been shown to be involved not only in cellular
stress response, differentiation, senescence, and apoptosis, but
also in neurodegeneration, inflammation, cancer, and infections.
Several reviews were dedicated to this lipid [42–47]. Accord-
ingly, a wide range of ceramide effects has also been reported in
neural cells [46,48–50]. At first glance these effects often
appear to be contradictory and conflicting, reaching from
promotion of cell survival to induction of apoptosis. However, a
deeper examination of the data reveals several circumstances to
be responsible for inconsistent results: (i) the diversity of neural
cells as well as their developmental and physiological state, (ii)
the concentration of ceramide employed, and last but not least,
(iii) the influence of surface dilution, relevant especially in cells
with extensive plasma membrane surfaces, characteristic for
many neural cell types [46]. From the considerable number of
studies documenting the physiological role of ceramide, we
want to point only to one representative report by Riboni et al.
[51]. In this study an impressive correlation of cellular ceramide
content and the malignancy of human glial tumours has been
established [51]. Despite all these findings concerning ceramide
functions, this compound might not be the centre of cellular
control, but it surely is the central molecule in SL metabolism
(Fig. 3). On one hand it is the biosynthetic precursor of all GSLs
and of all phosphosphingolipids like sphingomyelin, and on the
other hand their catabolic intermediate. Importantly, sphingo-
sine can be formed only via ceramide and simultaneously this
long chain base is the first breakdown product of ceramide (Fig.
3). Alternatively, sphingosine can be re-acylated to ceramide,
thus representing the starting point of the SL salvage pathway.
2.1. Formation and intracellular transport of ceramide
Most of our knowledge concerning de novo ceramide
biosynthesis comes from studies on rat liver and the pioneering
work was done during the 1960s by the group of W. Stoffel [52].
The first steps of sphingolipid biosynthesis leading to the
formation of dihydroceramide (Fig. 3) are catalyzed by
membrane-bound enzymes active at the cytosolic face of the
endoplasmic reticulum (ER) (for review see [53].
The crucial finding that sphingosine is not a de novo
biosynthetic intermediate of ceramide formation comes from
studies in neuroblastoma cells [54]. In these cells dihydroceramide
desaturase was highly specific for dihydroceramide and did not
accept sphinganine (dihydrosphingosine) as a substrate. This was
the first experimental proof for the generally accepted sequence of
biosynthetic steps leading to ceramide formation (Fig. 3).
Apart from the de novo biosynthesis from simple molecules
(serine and a fatty acid) ceramide can also be formed from the re-
acylation of sphingosine as observed in primary cultures of
neurons and astrocytes, and also in several neuroblastoma cell
lines [55–57].
A characteristic feature of neuronal (dihydro)ceramide
synthase is its higher affinity for stearoyl—and lignoceryl
CoA than for palmitoyl CoA [58]. This enzyme activity was
measured in the microsomal fraction isolated from primary
cultured cerebellar neurons and was strongly inhibited by
fumonisin B1 (FB1) [58]. Apart from the fatty acyl CoA-
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synthesis of ceramide from sphingosine and free fatty acid and
the reverse reaction, namely hydrolysis of the amide bond of
ceramide yielding sphingosine and free fatty acid, was purified
from rat brain 40 years ago [59]. This enzyme had a pH
optimum at 4.8 and required detergents to be active. A non-
lysosomal membrane-bound isoform of this ceramide-synthase/
ceramidase activity was purified from rat brain and intensively
studied during the past few years [60,61]. Both, the rat enzyme
as well as the cloned human homologue [62] were localized to
the mitochondria with cardiolipin stimulating the ceramidase
activity in vitro. In addition, the mitochondrial protein does not
share the FB1 sensitivity of the ER resident enzyme.
Concerning its substrate specificity, the mitochondrial enzyme
prefers myristic acid and only poorly N-acylates the three
unnatural stereoisomers of sphingosine [62].
These findings shed new light on previously performed
inhibition experiments with FB1 in primary cultured neurons
[58]. Despite a considerable impairment of neuronal de novo
biosynthesis of SLs, including GSLs and sphingomyelin in the
presence of FB1, no reduction of SL mass was detectable [58].
Based on the awareness that an FB1 insensitive ceramide-
synthase activity does exist in the brain, one is tempted to
speculate that this enzyme might have rescued SL mass in
neurons despite a substantially reduced de novo biosynthesis. Of
interest, 1-methylthiodihydroceramide, a metabolically stable
structural analogue of dihydroceramide (Fig. 3) also seriously
inhibited de novo ceramide biosynthesis (by 90%) with only
trivial reduction of SL mass (15% after 96 h) in primary cultured
neurons [63]. In contrast to FB1 that caused considerable
accumulation of sphinganine, 1-methylthiodihydroceramide
acted as a “sphinganine scavenger” by stimulating its phosphor-
ylation and degradation and thereby depleting neurons of a vital
precursor of de novo ceramide formation. We therefore,
speculated that elevated amounts of dihydroceramide might
reduce de novo SL biosynthesis by up-regulating the degrada-
tion of its biosynthetic precursor [63]. In conclusion, de novo
formed ceramide appears to come from the ER, whereas
recycled ceramide comes from other subcellular sites, one
being the mitochondria. Further metabolic transformation of
ceramide is mapped to the Golgi compartment (see below) thus
implying ceramide transport through the cytosol. The ceramide
transport problem has been covered in a recent review by
Hannun and Luberto [64]. Being one of the most hydrophobic
and thus stickiest molecules in the cell, ceramide is most
probably much less mobile than its precursors, the long chain
bases. This might also explain the occurrence of several iso-
enzymes allowing formation of ceramide at different sub-
cellular sites (see above).
Although it is generally accepted that intra-cellular transport
of lipids is vesicle-mediated [65], there is experimental evidence
that ceramide does not rely on vesicles to reach the GolgiFig. 3. Ceramide, the central molecule of sphingolipid metabolism. Green arrows: pat
formation; red arrows: biosynthetic pathways using ceramide as a precursor; black
degradation of ceramide. Note that fumonisin B1 (FB1) inhibits de novo formation of
used are: C1P, ceramide-1-phosphate; PLP, pyridoxal phosphate; S1P, sphingosine-1apparatus [66]. How this non-vesicular ceramide transport
occurs has been unclear for a long time. First experimental
approaches indicated that the major pathway by which ceramide
is transported from the ER to the Golgi apparatus is ATP- and
cytosol-dependent [67,68]. CERT, the first and so far single
ceramide transport protein was discovered in a mammalian
mutant cell line, LY-A, in which the major pathway of ceramide
transport to the Golgi is genetically impaired [69]. From its
amino-acid sequence CERT was predicted to be a cytoplasmic
protein with a START domain corresponding to a structural
region that in other proteins forms a deep lipid-binding pocket
[70]. In addition CERT has two motifs known to be involved in
subcellular targeting: a pleckstrin homology domain (PH) that
can target the Golgi apparatus [71] and a FFAT motif that can
bind VAP, an ER membrane anchored protein [72].
From the discovery of CERT, we learned that extraction and
delivery of ceramide appears to be quite specific [69]. It was
thus suggested that CERT is involved only in sphingomyelin
formation and not in the formation of GlcCer, although both
SLs are formed in an early Golgi compartment albeit at the
luminal and cytosolic membrane faces, respectively. It was also
suggested that CERT is regulated by PI-4 phosphate, a lipid
enriched in Golgi membranes. It would be interesting to study
CERT in neurons, where the formation of sphingomyelin and
GlcCer were located to different subcellular compartments: the
TGN (trans-Golgi network)/plasma membrane [73] and a pre-
Golgi compartment, most probably the ER [53,74], respec-
tively, (see also below).
In neurons several findings point to a potential role of
cytoskeleton proteins in ceramide transport. Using a photo-
affinity labelling approach, we identified tubulin and vinculin to
specifically bind ceramide in neural cells [75]. Our findings
were confirmed by immunofluorescent cell staining experi-
ments, which revealed a co-distribution of tubulin and ceramide
in embryonic cells [10]. In addition, studies with cells lacking
vimentin intermediate filaments clearly indicate the involve-
ment of cytoskeleton particularly in the salvage pathway of SL
formation [76], possibly in the transport of ceramide from
mitochondria to the Golgi stack.
2.2. Degradation of ceramide
The extent of the physiological importance of ceramide
degradation was recognized with the discovery of the signalling
function of its breakdown product sphingosine-1-phosphate
(S1P) (see also chapter by S. Spiegel, this volume). A family of
ceramidases, which differ in their pH optimum as well as in
their subcellular localization, hydrolyse ceramide to generate
sphingosine, which is then either phosphorylated to S1P or
reused for ceramide formation via a salvage pathway (Fig. 3).
Interestingly, acid ceramidase appears to be a major
glycoprotein in human brain being mainly expressed in neuronshway of de novo ceramide formation; blue arrows: salvage pathway for ceramide
arrows: catabolic pathways yielding ceramide as an intermediate; grey arrows:
ceramide at the level of sphinganine N-acyltransferase in neurons. Abbreviations
-phosphate.
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enzyme was found to be elevated in Alzheimer's disease brain
co-localizing with neurofibrillary tangles, thus suggesting an
involvement in neurofibrillary degeneration [77]. So far no data
concerning the amount of ceramide, the substrate, as well as of
sphingosine, the product of acid ceramidase catalyzed reaction
are available in Alzheimer's disease brain. Importantly,
sphingosine is a metabolic intermediate whose fate is decisive
for cellular SL content. Its N-acylation back to ceramide is
essential for the salvage pathway, which was shown to be the
main way of GSL formation especially in slowly dividing cells
[78]. Whereas phosphorylation of sphingosine to S1P, that is
rapidly and irreversibly cleaved by the respective lyase (Fig. 3)
induces a net reduction of cellular SL content.
2.2.1. Sphingosine-1-phosphate
Both reactions that lead to the formation of S1P from
ceramide are reversible, indicating a closely interconnected
metabolism of these two bioactive SLs (Fig. 3). In most cell
types ceramide and S1P exert antagonistic effects on cell
survival. S1P was reported to rescue cells from ceramide
mediated apoptosis [79]. In neural tissue, however, the
situation is apparently more complex and as shown above
for ceramide, also in case of S1P the biological effects are
dependent on several conditions including the grade of
neuronal differentiation. Thus S1P induces proliferation in
neural progenitor cells [80], but apoptosis in differentiated
hippocampal neurons [81]. Primary cultured neurons despite a
considerable sphingosine kinase activity (see below), prefer-
entially direct exogenously added sphingoid bases including
sphingosine, dihydrosphingosine and safingol (L-threo-dihy-
drosphingosine) towards ceramide and GSL formation
[55,56,82]. By contrast, cis-4-methylsphingosine, a synthetic
structural analogue of sphingosine with a cis instead of the
trans double bond and a methyl-group at carbon 4, is
exclusively phosphorylated and not used as a precursor for
ceramide and complex SLs formation [83]. Interestingly, cis-
4-methylsphingosine-phosphate proved to be lyase resistant,
thus accumulating intracellularly. More interestingly, relative
accumulation of this synthetic sphingoid-phosphate was
highest in post-mitotic differentiated neurons [84], followed
by neuroblastoma cells [85] and lowest in fibroblasts [86],
indicating a considerable metabolic activity toward sphingoid
base phosphorylation especially in differentiated neurons. The
physiological significance of these observations is not yet
clear. But in analogy to previous findings with S1P in
hippocampal neurons [81], accumulated cis-4-methylsphingo-
sine-phosphate increased intracellular free calcium levels (van
Echten-Deckert et al., unpublished observation) and induced
apoptosis [84] in cerebellar neurons. In addition, its
accumulation was accompanied by a down-regulation of
serine palmitoyltransferase (SPT), known to catalyze the rate-
limiting step of de novo ceramide formation [83]. Our
hypothesis, that high levels of sphingoid-phosphates might
exert a feed-back down-regulation of the enzyme catalyzing
the initial step of de novo SL biosynthesis was supported by
observations of S. Spiegel's group [87]. Importantly, albeit aless active SPT in the presence of cis-4-methylsphingosine,
the mass of SLs in neurons did not change [83], pointing
again towards the importance of salvage mechanisms in
maintenance of SL homeostasis in neurons.
A novel function of S1P in neural development has been
reported very recently [88]. In contrast to sphingosine kinase
1 or 2, single-mutant mice [88,89] that do not show markedly
decreased S1P contents in tissues and lack obvious abnorm-
alities, simultaneous disruption of both known sphingosine
kinase genes causes complete deficiency of S1P and
embryonic lethality [88]. In addition to expected defects in
vascular development, which were previously shown to
depend on S1P1 receptor mediated signalling [90], these
double knockout mice exhibited severely disturbed neurogen-
esis including neural tube closure [88]. S1P deficient mice
revealed increased cell death particularly during neural tube
closure periods and reduced cell proliferation in the
neuroepithelial layer, which were also observed, albeit to a
considerably lesser extent, in S1P1 receptor deficient murine
embryos. Although in the latter no neural tube defects could
be detected, the synergism of results indicates that the effect
of S1P on neurogenesis is mediated, at least in part, by the
S1P1 receptor. Note that implications of SL metabolism in the
pathogenesis of human neural tube defects have been
suggested previously [91].
2.3. Ceramide—an intermediate of phosphosphingolipids
Phosphosphingolipids are a class of hybrid lipids with a
similar hydrophobic membrane anchor like SLs and the polar
headgroup of phosphoglycerolipids. Ceramide-1-phosphate
(C1P) is the simplest phosphosphingolipid and corresponds to
phosphatidic acid (diacylglycerol-phosphate). The major repre-
sentative of this class of hybrid lipids in mammalian tissues is
sphingomyelin, which has the same polar group like phospha-
tidylcholine, but attached to ceramide, instead of diacylglycerol.
Small amounts of phosphoethanolamine-ceramide and of
phosphoglycosphingolipids have also been detected in some
organisms, including mammals.
2.3.1. Ceramide 1-phosphate
Phosphorylation/dephosphorylation reactions represent an
important strategy that allows cells to rapidly respond to
changes of the milieu, since the phosphorylated state of a
molecule often exhibits effects that are diametrically different
from those of the unphosphorylated state. It is thus not
surprising that phosphorylation of ceramide allows a switch
from apoptosis towards survival (see also the chapter by A.
Gomez-Munoz, this volume) in diverse cell types. According
to the quite different effects of ceramide in neural tissue [46]
it appears likely that ceramide-1-phosphate (C1P) might also
display different functions depending on neural cell type as
well as on the developmental and the physiological state of
the cells. It has indeed been shown that primary cultured
neurons display quite different capacities to produce C1P
depending on their stage of differentiation [92]. It appears
that at least two different ceramide kinases exist in neural
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level associated with rat brain synaptic vesicles [93] and a
second cytosolic enzyme [94]. Also, a C1P phosphatase
associated with both, synaptic vesicles and plasma mem-
branes has been described [95]. Although the physiological
significance of C1P in neural tissue still awaits clarification,
a role in neurotransmitter release has been proposed due to
the synaptic localization of the enzymes involved in its
metabolism [95].
2.3.2. Sphingomyelin
Sphingomyelin accounts for about 10% of mammalian
cellular lipids and is preferentially concentrated in the outer
leaflet of the plasma membrane of mammalian cells. Originally,
it was considered to be mainly a structural element of the plasma
membrane, providing a rigid barrier to the environment. Since
the discovery of the “sphingomyelin cycle” as an ubiquitous,
evolutionarily conserved signalling system analogous to well
known second messenger systems such as the cAMP and
phosphoinositide pathway, sphingomyelin hydrolysis is con-
sidered to be the main pathway for production of ceramide used
in signal transduction [96,97].
Sphingomyelin is synthesized by the transfer of phosphocho-
line, the water-soluble phospholipid specific head group from
phosphatidylcholine, onto ceramide liberating diacylglycerol
[98] (Fig. 3). Conflicting results have been reported with regard
to the subcellular localization of sphingomyelin formation (for
review see [53]). It was suggested that 90% of de novo
sphingomyelin synthesis occurs in the cis/medial Golgi and
only a small percentage in the plasma membrane. However, in
neural cells including cerebellar neurons and neuroblastoma
cells most of the de novo sphingomyelin is synthesized in a non-
Golgi location, most probably the plasma membrane and
possibly the trans Golgi network [73,99], indicating a cell type
specific subcellular localization of bulk sphingomyelin forma-
tion. An attractive model, for which compelling experimental
evidence is available, proposes sphingomyelin formation in the
endocytic recycling pathway [100]. This model also explains
the dramatic difference between the lipid composition of the
plasma membrane and that of intracellular membranes, in
particular that of the ER, the main site of lipid biosynthesis.
Sphingomyelin, cholesterol, and glycolipids are abundant in the
plasma membrane and are scarce in the ER, which is rich in
phosphatidylcholine and phosphatidylinositol.
The most intriguing property of sphingomyelin is its effect on
cholesterol metabolism and especially on the rate of cholesterol
dissociation from membranes [101]. Thus, it is not surprising
that halothane and other anaesthetics known to stimulate
sphingomyelin degradation by activating membrane-bound
neutral sphingomyelinases, were shown to increase membrane
fluidity in synaptosomal plasma membranes [102]. The elevated
membrane fluidity was accompanied by an activation of
membrane-bound neuraminidase, and as a consequence, an
increased degradation of gangliosides [103]. These studies were
performed a quarter century ago, long before the discovery of the
sphingomyelin cycle [96], which adds a new dimension to those
findings and the consequences derived thereof. It has beenproposed that ceramide formed by sphingomyelin hydrolysis
might provide the driving force in the coalescence of micro-
scopic rafts into large membrane macrodomains, which serve as
platforms for signal transduction [43].
Although disorders concerning sphingomyelin degradation,
like Niemann–Pick disease types A and B caused by an acid
sphingomyelinase deficiency do not necessarily affect the
central nervous system (Niemann–Pick type B) [104], the
importance of sphingomyelin homeostasis for the brain is
undoubted. As mentioned already in Introduction sphingomye-
lin metabolism is closely interconnected with that of cholesterol
and both are involved in the processing of the amyloid precursor
protein, while metabolites of the latter regulate homeostasis of
cholesterol and of sphingomyelin [23].
2.4. Glycosylation of ceramide
Despite the fact that formation of ceramide has been shown
to occur in different subcellular compartments, glycosylation
steps appear to be restricted to the ER-Golgi complex. The
stepwise addition of sugar molecules to ceramide is catalyzed
by membrane bound glycosyltransferases and is accompanied
by the exocytotic vesicular membrane flow of the growing
molecules from the ER through the Golgi cisternae to the
plasma membrane [53]. Due to the abundance of GSL in neural
tissue many glycosyltransferases involved in biosynthesis of
these lipids were first detected in the brain [105]. In the mid
1960s essential pioneering work on localization and character-
ization of these membrane bound enzymes has been performed
particularly in the laboratory of S. Roseman using a particulate
preparation from embryonic chicken brain [106,107]. An
essential step towards understanding the molecular mechanism
of glycosylation reactions were molecular cloning and expres-
sion studies of glycosyltransferases performed in the 1990s,
especially in Japan [108–111]. We recommend two excellent
reviews concerning the molecular topology [112] and the
potential mechanism of catalytic reaction [113] of glycosyl-
transferases, respectively.
2.4.1. Biosynthesis of monohexosylceramides
Interestingly, despite the huge number of known GSL
structures, only two sugar molecules namely glucose and
galactose have been found to be directly attached to ceramide
leading to glucosylceramide (GlcCer) and galactosylceramide
(GalCer), respectively. Even more interestingly, whereas GalCer
is submitted to either sulphation [114] to form sulfatide,
sialylation to form ganglioside GM4, or further galactosylation
to form Gal2Cer the precursor for a rather restricted number of
gala-series GSLs, GlcCer is mainly galactosylated to lactosyl-
ceramide, which is the common precursor for all other GSLs (for
review see [53]). Both monohexosylceramides are particularly
important in neural tissue. As depicted in Fig. 2 GalCer is most
abundant in oligodendrocytes, whereas GlcCer is the precursor
for all gangliosides that are abundant in neurons.
2.4.1.1. Galactosylation of ceramide. First of all it should be
emphasized that GalCer and its sulphated derivative sulfatide
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specialized plasma membrane of oligodendrocytes and
Schwann cells, which is essential for the saltatory nerve
conduction in vertebrates (see Figs. 1 and 2). Galactosylation of
Cer is catalyzed by ceramide galactosyltransferase (CGalT or
CGT) [116–118], an enzyme that is expressed not only in
oligodendrocytes, but also in other neural cells including
neurons and astrocytes [119]. The subcellular localization and
topology of CGalT was subject of a series of conflicting
debates, in which it was mapped to the luminal face of the ER or
to the cytosolic face of the early Golgi compartment (for review
see [53]). Finally, it became clear that CGalT is localized in the
ER and the nuclear envelope with a luminal orientation of its
catalytic site [120]. It became also clear that CGalT activity,
formerly detected in Golgi fractions, was due to the capability of
glucosyltransferase to synthesize not only GlcCer but also
GalCer in the presence of UDP-Gal and absence or low UDP-
Glc in vitro [120]. The luminal topology of galactosylation
implies a translocation of ceramide from the cytosolic side,
where it is formed to the luminal side of membranes. Further
glycosylation and sulphation of GalCer exhibit a similar luminal
topology, but are localized to the Golgi compartment [121].
The critical role of CGalT and sulfatide in oligodendrocyte
development and myelin formation was suggested about three
decades ago [122,123]. In mice lacking GalCer, due to CGalT
deficiency, this assumption has finally been confirmed
[124,125]. Thus, in these animals the formation of an
unstable, functionally affected myelin leads to a progressive
demyelination accompanied by severe motor coordination
deficits [125]. Interestingly, the unstable myelin in these mice
contained GlcCer, which usually is not a myelin component.
More interestingly, this GlcCer contained ceramide with an α-
hydroxylated fatty acid (HFA), which is rather unusual but is
well known in GalCer, HFA-ceramide being the preferred
substrate for CGalT [126]. However, the question of which
circumstances allow preferential galactosylation of non-
hydroxy fatty acid (NFA)-ceramide or of α-hydroxy fatty
acid (HFA)-ceramide still remains unanswered. Recent studies
with transgenic mice expressing CGalT under the control of
an oligodendrocyte-specific promoter indicate that only NFA-
GalCer formation is limited by CGalT activity. As a
consequence, in these transgenic mice HFA-GalCer decreased
and NFA-GalCer increased resulting in an unchanged overall
GalCer content [127]. Remarkably, the phenotype of CGalT
deficient mice could be rescued with a CGalT transgene
under the control of an oligodendrocyte-specific promoter,
whereas this was not the case under a neuron-specific
promoter [127]. It thus appears that oligodendrocyte asso-
ciated CGalT is responsible for the deficits in myelin
structure, demyelination and behavioural abnormalities of
CGalT deficient mice.
2.4.1.2. Glucosylation of ceramide. Apart from the fact that
GlcCer is the most abundant GSL in most cells, it is the
common precursor for virtually all GSLs except those derived
from GalCer (see above). Its essential role for neuronal
development became obvious mainly from studies performedby A. H. Futerman's group [33]. Disruption of the Ugcg gene
encoding for UDP-glucose: ceramide β1,1- glucosyltransferase
(CGlcT) demonstrated the vital role of GSL biosynthesis not
only in neuronal development, but also for embryonic
development and early differentiation [128]. In the absence of
GlcCer biosynthesis embryonic lethality occurred at the
gastrulation stage indicating a critical role of GlcCer derived
GSLs in morphogenesis.
Many years passed from the first assays on glucosylation of
ceramide performed in embryonic chicken brain [129] and
purification, characterization, and cloning of CGlcT [108,130].
Interestingly, this enzyme does not show any sequence
homology with CGalT despite the similarity of reactions
catalyzed. In contrast to all other SL glycosyltransferases,
CGlcT is a type III transmembrane protein forming dimers or
oligomers [131] mediated by the cytosolic C-terminal domains
[108]. Thus, in contrast to all other GSLs, which are located
exclusively in the outer (anticytosolic) leaflet of the plasma
membrane, GlcCer is distributed in both, the outer (antic-
ytosolic) and the inner (cytosolic) leaflet of the plasma
membrane. Early metabolic studies from our laboratory at
reduced temperature (15 °C), a condition shown to arrest
vesicular transport from the ER to the Golgi complex, indicated
that in neurons the initial glycosylation of ceramide occurs in a
pre-Golgi compartment, most probably the ER [74]. By contrast,
in non-neuronal tissues CGlcT was found to be primarily
associated with the Golgi compartment (for review see [53]).
2.4.2. Biosynthesis of lactosylceramide
Lactosylceramide (LacCer) is formed by galactosylation of
GlcCer catalyzed by UDP-galactose:GlcCer β1,4-galactosyl-
transferase formerly called Gal-T-2 to distinguish it from CGalT
(see above) also known as Gal-T-1. In a series of papers LacCer-
synthase was also called GalT-I to distinguish it from GM1-
synthase (GalT-II, see below). LacCer is the branching point for
all GSL-series except the gala-family (see above). Its biosynth-
esis was first described in vitro in embryonic chicken brain
tissue enriched in Golgi bodies [107], but LacCer-synthase was
initially purified from human kidney [132] and later purified
and cloned from rat brain [109]. Conflicting results have been
reported on the topology of this enzyme, which was finally
mapped to the luminal face of the early Golgi compartment
[133–135]. This implicates a translocation of that pool of
GlcCer designated for further glycosylation from the cytosolic
to the luminal face of Golgi membranes. The main pool of
newly synthesized GlcCer was, however, shown to be rapidly
transported to the plasma membrane by a direct route
independently of the exocytotic vesicular membrane flow
through the Golgi compartment probably mediated by lipid
transfer proteins [136–138]. It is still not clear which factors
direct GlcCer towards LacCer-synthase or how this occurs. An
interesting study performed in primary cultured neurons in
which a synthetic structural GlcCer-analogue was used,
indicates that LacCer synthase itself might act as a “flippase”
and catalyze membrane translocation of its substrate [139].
However, one cannot definitely exclude that the broad lipid
translocating multi-drug resistance (MDR1) P-glycoprotein,
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also active at the level of Golgi membranes in neurons.
2.4.3. Biosynthesis of gangliosides
As depicted in Fig. 2 gangliosides are particularly enriched
in neurons and GD1a and GT1b represent the major ganglio-
sides in mammalian brain. Sequential addition of sialic acid and
monosaccharide residues to the growing oligosaccharide chain
is catalyzed by membrane bound glycosyltransferases, which
are shown to be restricted to the luminal leaflet of the Golgi
membrane [141–144]. For detailed information concerning the
organization and characterization of these glycosyltransferases
we recommend the reviews of Maccioni et al. [112] and of Basu
et al. [105]. We only want to emphasize that all glycosyl-
transferases involved in GSL metabolism, except CGlcT (see
above) are type II transmembrane proteins with a domain
organization consisting of a large luminal C-terminus bearing
the catalytic site, a stem region, a transmembrane uncleaved
signal anchor domain, and a short cytosolic N terminus.Fig. 4. Proposed model for ganglioside biosynthesis in neurons. Ceramide formation
glycosylation steps were mapped to the luminal face of Golgi membranes. GM3 and G
the action of specific sialyltransferases (SAT I and II) in the proximal Golgi compartm
are then transported via vesicles to the distal Golgi compartment (TGN) where rat
proposed to form a multi-enzyme complex. Abbreviations used are (i) for lipids
galactosamine; Glc, D-glucose; GlcNAc, N-Acetyl-glucosamine; NeuAc, N-Acetylne
GalT I, galactosyltransferase I (lactosyl synthase); GalT II, galactosyltransferase II (G
GD2 synthase); SAT I, sialyltransferase I (GM3 synthase); SAT II, sialyltransferase
terminology used for gangliosides is that of Svennerholm [193].The model for ganglioside biosynthesis initially proposed by
Pohlentz et al. [145] based on kinetic studies performed in rat
liver Golgi has been recently introduced as a combinatorial
synthetic concept [146]. Here we refer only to the a- and b-
series of gangliosides that are abundant in neuronal tissue (Fig.
4). The precursors of these two ganglioside series are GM3 and
GD3, respectively, two gangliosides formed by the sequential
addition of two sialic acid residues to LacCer. Thus the number
of sialic acid residues at the inner galactose determines to which
series a ganglioside belongs. Interestingly, the formation of
these precursors is catalyzed by two highly specific sialyl-
transferases, SAT I and SAT II, whereas the subsequent
glycosyltransferases including N-acetylgalactosamine transfer-
ase (GalNAcT or GM2/GD2 synthase), galactosyltransferase II
(GalT II or GM1a/GD1b synthase), as well as SAT IV (GD1a/
GT1b synthase) are rather unspecific and do not distinguish
between substrates with different sialic acid residues on their
inner galactose. Much effort has been spent to determine the
sub-Golgi location of these glycosyltransferases (for review seeand its glucosylation occur at the cytosolic face of ER membranes. All the other
D3, the precursors of a- and b-series of gangliosides, respectively, are formed by
ent comprising cis-, medial-, and trans-Golgi stacks. The precursor gangliosides
her unspecific glycosyltransferase activities, depicted by the shaded areas, are
: Cer, Ceramide, N-Acylsphingosine; Gal, D-galactose; GalNAc, N-Acetyl-D-
uraminic acid; (ii) for glycosyltransferases: CGlcT, ceramide glucosyltransferase;
M1a/GD1b synthase); GalNAcT, N-Acetyl-D-galactosaminyltransferase (GM2/
II (GD3 synthase); SAT IV, sialyltransferase IV (GD1a/GT1b synthase). The
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in murine cerebellar neurons [99,147] and in H. Maccioni's
laboratory using chick retina cells [148–150] mapped the
synthesis of GM3 and GD3, the precursors of the a-, and b-
pathway to the proximal (cis-, medial-, and trans-Golgi) and that
of all the other gangliosides to the distal (TGN, trans Golgi
network) Golgi compartment. Elegant studies concerning the
possibility of a physical and functional association of
glycosyltransferases of the distal Golgi stack [151] strongly
support the idea of “cooperative sequential specificity” in the
synthesis of complex oligosaccharides by multi-glycosyltrans-
ferase systems, raised almost 40 years ago [141]. Coimmuno-
precipitation experiments with epitope tagged versions of
GalNAcT and GalT II showed that immunocomplexes were
catalytically active in vitro. In addition, in vivo determination of
fluorescence resonance energy transfer (FRET) between cyan
and yellow fluorescent proteins fused to the N-terminus of the
transferases showed that these domains associated closely
enough (1–10 nm) in Golgi membranes to allow energy transfer
between the fluorophores [151]. The idea that a limited number
of precursors formed in the proximal Golgi compartment is
passed to a multi-enzyme complex in the distal Golgi stack is
quite attractive especially when considering (i) the ganglioside
profile of vertebrate neurons exhibiting predominantly pre-
cursor gangliosides GM3 and GD3 during early stages and
complex gangliosides particularly, D1a and GT1b during later
stages of development, respectively [152], and (ii) that a
substantial number of rather unspecific glycosyltransferase
activities co-localize in the same sub-Golgi compartment. In
mammalian neurons, known to express only a- and b-series
gangliosides and none of the 0-series gangliosides that derive
directly from LacCer, one would assume that LacCer does not
reach this multi-enzyme complex in the late Golgi compartment
being almost completely sialylated in the early Golgi stack.
Conversely, in transgenic mice lacking SAT I activity LacCer
obviously reaches the multi-enzyme complex being processed
particularly to GM1b, the 0-series equivalent of GD1a and
GT1b of a- and b-series gangliosides, respectively [27].
The amount of a-versus b-series gangliosides appears to be
regulated by the availability of the respective precursor. Thus the
main regulation site might be at the level of precursor formation
catalyzed by highly specific SAT I and II. An experimental
support for this idea is provided by studies in cerebellar neurons
in which an acid pH known to be optimal for SAT II activity not
only favoured GD3 formation, but as a consequence of more
available b-series precursor, induced a shift from a-pathway to b-
pathway [153]. Of interest, the proposed model of neuronal
ganglioside biosynthesis also offers an explanation for the
relative subtle effects in the nervous system of mice with
disruptions in key glycosyltransferase genes involved in gang-
lioside biosynthesis. Thus, the brains of mice deficient in
GalNAcT (GM2/GD2-synthase) contain large amounts of the
precursor gangliosides GM3 and GD3, which obviously
compensate the lack of complex ganglioside at least regarding
development of brain morphology [24]. Albeit having a nearly
normal lifespan thesemice exhibit certain motor function defects
with age [154] and also show demyelination and axonaldegeneration in optic and sciatic nerves [155]. Furthermore,
brains from mice deficient in SAT II (GD3-synthase) activity
completely lack b-series ganglioside but express elevated
amounts of a-series gangliosides instead and exhibit again an
almost normal phenotype [26,28]. As predicted by the proposed
model, simultaneous deactivation of both, SAT II and GalNAcT
allows only the formation of GM3 from all brain gangliosides.
These “GM3 only” mice have a shortened lifespan, peripheral
nerve degeneration and exhibit fatal audiogenic seizures
[28,156]. As mentioned above, the absence of SAT I activity
alone, still allows formation of 0-series gangliosides in the brain,
which probably rescue mice carrying this defect from conspic-
uous neurological anomalies [27]. However, simultaneous
deactivation of SAT I and of GalNAcT causes a complete
interruption of ganglioside biosynthesis, which is accompanied
by a severe phenotype [29]. Although these ganglioside null
mice are viable, they exhibit rapid and profound degeneration in
the central nervous system [29]. It thus appears that at least for
brain morphology the amount of ganglioside (quantity) is
essential, whereas for the correct function certain molecular
ganglioside species (quality) are required.
Apart from the availability of certain precursors (see above),
further mechanisms are involved in the regulation of neural
GSL content [157]. Most of them are similar to mechanisms
known from other metabolic pathways and include transcrip-
tional control of glycosyltransferase expression [158–160],
post-translational modifications including phosphorylation
[161–163], and N-glycosylation [164] of glycosyltransferases,
availability of sugar nucleotides [165,166], and feed-back
inhibition of initial steps by end products [167,168].
The complexity of neuronal GSL metabolism resides at the
one hand in the considerable number of minor GSL species
which are only locally and temporary expressed and on the other
hand in the developmental specific changes of the sphingoid
backbone of certain GSL species. Thus in the adult cerebellum
sulfoglucuronyl glycolipids (SGGLs) are specifically localized
in Purkinje cells and their dendrites in the molecular layer
whereas major cell types including granule neurons and glial
cells lack these SGGLs [169]. Interestingly, immature granule
neurons are capable of synthesizing SGGLs but lose this
capacity with maturation. Also, SGGLs are maximally
expressed in cerebral cortex at embryonic days 18–20 and
almost disappear by postnatal day 15 [170,171]. Another
characteristic of neuronal cells is their content of gangliosides
that contain a longer sphingoid base bearing 20 instead of the
usually found 18 carbon atoms. Interestingly, these longer
molecular species are lacking in undifferentiated cells but appear
with onset of differentiation and then increase continuously
throughout life span (for review see [172]). Although the
existence of these gangliosides in neurons is known since
40 years [173] neither the regulation of their metabolism nor
their physiologic significance are known. These two examples
are representative for a considerable number of similar findings
that reflect the complexity of neuronal GSL metabolism.
2.4.3.1. Gangliosides in neuroblastoma. Increasing evidence
has implicated gangliosides in the biological and clinical
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neuroblastoma [174]. Gangliosides were shown to be shed
by tumour cells thereby altering their microenvironment,
which often favours malignancy [175]. Interestingly, not only
aberrant ganglioside structures, but also an aberrant metabo-
lism of “correct” gangliosides could be correlated with
tumour malignancy [176]. Although ganglioside metabolism
is known to vary among neuroblastoma tumours [177–179],
the absence of complex gangliosides is quite striking (see also
Fig. 2). Although neuroblastoma cells B104 are devoid of b-
series gangliosides pointing to a SAT II deficiency, this
enzyme was active when assessed in cell homogenate in vitro
(van Echten-Deckert and Sandhoff, unpublished observation).
Why this enzyme is not active in situ remains an open
question. Previously discussed mechanisms including down-
regulation of enzymes at the transcriptional level [180],
aberrant enzymes or altered substrate affinity can be excluded
in case of B104 cells. A selective desialylation at the plasma
membrane level [181] of b-series gangliosides also appears
unlikely since plasma membrane sialidase should cleave all
outer sialic acid residues, including that of GM3, which,
however, is not the case in B104 neuroblastoma cells (Fig. 2).
A topological problem cannot be excluded at present,
although SAT II and its substrate GM3 should co-localize
in the proximal Golgi compartment (Fig. 4). Despite the lack
of an in depth understanding, the content of complex b-series
gangliosides evolved as a crucial marker for the clinical and
biological behaviour of human neuroblastoma [182]. A low
content of b-series gangliosides appears to be typical for
clinically most aggressive neuroblastoma phenotypes and thus
indicative for a poor prognosis [182]. Thus induction of
complex b-series gangliosides was proposed to reduce
neuroblastoma malignancy [183]. Indeed retinoic acid, a
pharmacological agent known to alter cellular ganglioside
metabolism was successfully applied in the oral maintenance
therapy of disseminated human neuroblastoma [184].
2.4.4. Degradation of glycosphingolipids
Cell surface lipids display a highly dynamic nature, being
continuously internalized via endocytosis and recycled back to
the plasma membrane [185]. The significance of this circular
flow is largely unknown, but was proposed to play a key role
in plasma membrane lipid composition [100]. Components of
the plasma membrane, including GSLs, which are destined for
degradation pass through the endosomal compartment as
intraendosomal vesicles that finally become intralysosomal
vesicles or membrane fragments [186]. Within the lysosome,
degradation of GSLs occurs by the stepwise action of specific
acid exohydrolases, starting at the hydrophilic end of the
molecule (see the chapter by T. Kolter and K. Sandhoff, this
volume). More than ten different exohydrolases are known to
be involved in GSL degradation. The deficiency of any one of
the degrading hydrolases can cause an accumulation of the
corresponding lipid substrate in the lysosomal compartment,
leading to the so-called sphingolipid storage diseases. In these
inherited diseases, accumulation of lipids occurs mainly in
those cell types and organs in which the lipids arepredominantly synthesized, although acid hydrolases are
present in all the cells of the organism with the exception of
human erythrocytes. Therefore, the brain is mainly affected by
ganglioside storage disorders [187]. In contrast to membrane
bound glycosyltransferases catalyzing GSL biosynthesis,
exohydrolases involved in GSL degradation are water-soluble.
This fact obviously has a series of consequences. It has been
shown that enzymatic reactions, in which both, enzyme and
substrate are membrane bound, are independent of the
incubation volume indicating that the reaction proceeds mainly
at the cell surface or within individual membranes and not
through the aqueous phase [188]. It is assumed that
glycosyltransferases and their respective lipid substrates meet
via lateral diffusion within the membrane. In contrast water-
soluble exohydrolases can only act at the surface of membranes
containing their lipid substrate; thus, only recognize and cleave
oligosaccharide chains, which extrude far enough into the
aqueous space [189]. To degrade membrane bound GSLs with
short oligosaccharide chains these enzymes require the
assistance of small glycoprotein cofactors, the so-called
sphingolipid activator proteins (SAPs A–D or saposins A–D,
and the GM2 activator protein) [190]. Thus, the simultaneous
use of two components for GSL degradation might protect the
plasma membrane from inappropriate degradation. Cell
damage by missorted hydrolases ending up at the cell surface,
albeit at a low concentration, is prevented by both: the neutral
pH (hydrolases being fully active at a low pH) as well as the
low concentration of sphingolipid activator proteins at the cell
surface.
3. Concluding remarks
Given the diversity of neural cell types, it was a real challenge
to write a condensed review on their SL metabolism. We
therefore, decided to concentrate on some interesting aspects
that help the reader in understanding the “SL problem” in neural
tissue. It evolves more and more that SL metabolism is
essentially correlated with neuro-degeneration and neuro-
transformation. The largely unanswered question concerns the
circumstances that are causative for changes in SL metabolism
during the process of neuro-degeneration and during carcino-
genesis. To answer this question we have to define the factors
that direct SL intermediates towards certain metabolic pathways:
e.g. ceramide towards GSLs, sphingomyelin, C1P, or sphingo-
sine, GlcCer towards the plasma membrane without further
glycosylation or towards the Golgi lumen and formation of
complex GSL, GM3 towards a- or b-pathway of ganglioside
synthesis. Another question that should be addressed is on the
physiological function of several SL molecular species differing
only in the chain length and hydroxylation grade of their lipid-
anchors. With the introduction of more sensitive technologies
for SL analysis, the number of such SL molecular sub-species is
continuously growing. Since apparently certain extra- and
intracellular conditions preferentially affect only some of these
molecular sub-species [74] a systematic analysis of those sub-
species could help to understand regulatory mechanisms
governing SL metabolism.
1990 G. van Echten-Deckert, T. Herget / Biochimica et Biophysica Acta 1758 (2006) 1978–1994Despite the impressive accumulation of exciting information
concerning structure, metabolism, and physiological function of
SLs since their discovery in the brain by J.L.W. Thudichum in
1884, their “Sphinx”-derived name is still valid as many riddles
concerning this elusive lipid class are yet to be solved.
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